Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.…
Nutex Health (NUTX) Stock Dropped, So What Is Driving Attention Now?
Nutex Health (NASDAQ: NUTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 1,093 employees.
The shares were at 162.64 USD on 20 November 2026, up 33.6% over 52 weeks. Its 52-week range is 83.99 USD to 225.99 USD: the price is 28.0% below the high and 93.6% above the low.
At a market capitalisation of 1.12B USD, it trades at 7.0 times trailing earnings and 8.0 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, a discount of 70% for NUTX.
Nutex Health reports return on equity of 21.5%, an operating margin of 53.7% and revenue down 18.7% year over year.
Its debt exceeds its cash by 115.07M USD, a debt-to-equity ratio of 1.07. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 313.67 USD is 92.9% above the current price. The next earnings report is expected on 4 March 2027.